{"id":251040,"date":"2022-03-23T00:00:00","date_gmt":"2022-03-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/exincv0002-2022-biopharma-congenital-heart-block-executive-insights\/"},"modified":"2026-04-22T23:22:31","modified_gmt":"2026-04-22T23:22:31","slug":"exincv0002-2022-biopharma-congenital-heart-block-executive-insights-congenital-heart-block-executive-insights-us-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincv0002-2022-biopharma-congenital-heart-block-executive-insights-congenital-heart-block-executive-insights-us-eu5\/","title":{"rendered":"Congenital Heart Block &#8211; Executive Insights &#8211; Congenital Heart Block | Executive Insights | US\/EU5 | 2022"},"content":{"rendered":"<p>Congenital heart block (<abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns. Minimizing the deterioration of heart muscles and preventing disease progression are the key treatment goals in <abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>. No therapies are approved for <abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>, and patients are managed with off-label drugs such as dexamethasone and <abbr data-abbreviation-entity=\"5852\" title=\"Intravenous immunoglobulin\">IVIG<\/abbr>, or through plasmapheresis and pacemaker implantation. In addition, no commercial pharmacotherapies are in the pipeline for <abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>. A major unmet need is for effective therapies and represents a commercial opportunity for drug developers in this market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the diagnosed incidence of <abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>?<\/li>\n<li>What is the current market landscape including the diagnostic and management practices<\/li>\n<li>What are the current therapy and emerging therapy landscapes?<\/li>\n<li>What is the estimated cost of treatment in different geographies?<\/li>\n<li>What are the key unmet needs in the management of <abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>?<\/li>\n<li>What are the key market drivers and limiters?<\/li>\n<li>What are the opinions of <abbr data-abbreviation-entity=\"5534\" title=\"key opinion leader\">KOL<\/abbr>s on different aspects of <abbr data-abbreviation-entity=\"10291\" title=\"congenital heart block\">CHB<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.<\/p>\n<p><strong>GEOGRAPHY:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/p>\n<p><strong>PRIMARY RESEARCH<\/strong>: 13 <abbr title=\"key opinion leader\">KOL<\/abbr> interviews from November 2021 to January 2022<\/p>\n<p><strong>KEY DRUGS COVERED:<\/strong> Dexamethasone, intravenous immune globulin (<abbr data-abbreviation-entity=\"5852\" title=\"Intravenous immunoglobulin\">IVIG<\/abbr>)<\/p>\n","protected":false},"template":"","class_list":["post-251040","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251040\/revisions"}],"predecessor-version":[{"id":283484,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251040\/revisions\/283484"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}